trial

Ocrelizumab for Psychosis by Autoimmunity

NCTId NCT03971487
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Recruiting
Enrollment 40 (estimated)
Sponsored by The Methodist Hospital Research Institute
Primary completion 2028-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2019-10-01
Primary completion
2028-06-30
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Psychosis and cognitive assessmentsPhysical and neuro-cognitive evaluationsSafety labs and electrocardiogramOcrelizumab infusion

Sponsors

The Methodist Hospital Research InstituteLead Sponsor
Genentech, Inc.Collaborator

Investigators

1
Joseph C Masdeu, MD, PhDPrincipal Investigator

Sites

1 total
Houston, United States

Linked catalysts

1
Ocrelizumab for Psychosis by Autoimmunity — primary completion2028-06-30

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1,PHASE2
Primary Completion Date
2028-06-30
Status
RECRUITING
relationships
The graph out of here
drug
Psychosis and cognitive assessments
drug
Physical and neuro-cognitive evaluations
drug
Safety labs and electrocardiogram
drug
Ocrelizumab infusion
drug
lead_sponsor
The Methodist Hospital Research Institute
company
collaborator
Genentech, Inc.
company
indication
Schizophrenia
indication
Schizo-Affective Type of Psychosis
indication
Schizophrenia
indication
investigator
Joseph C Masdeu, MD, PhD
person